Flot.bio x Philip Hemme

Christian Angermayer became a multimillionaire before turning 25 thanks to the merger of Alnylam with Ribopharma. We talk about his diverse investment appetite and the rise of consumer biotech and human enhancement.We talk about GLP-1s, the progress of AtaiBeckley, and why he thinks ‘going home and sleeping’ beats an all-nighter every time.
---Discover the best biotech companies in 🇪🇺 with the FlotBio Map at https://bit.ly/4nXmKjN---
⭐️ ABOUT THE SPEAKER
Christian is the founder of Apeiron Investment Group, which manages around $7 billion across psychedelics, longevity, consumer biotech, crypto and media. He also co-founded big companies including AtaiBeckley and the Enhanced Games.Christian studied business in Germany at the University of Bayreuth but dropped out to co-found Ribopharma, which merged with Alnylam Pharmaceuticals in 2003.
🔗 LINKS MENTIONED
Christian Angermayer LinkedIn profile — https://www.linkedin.com/in/christian-angermayer/
Enhanced Games — https://www.enhanced.com/
Enhanced Games inaugural event press release — https://investors.enhanced.com/inaugural-enhanced-games-deliver-a-world-record-and-21-personal-bests-showcasing-that-living-enhanced-works/
David Nutt LinkedIn profile — https://www.linkedin.com/in/professor-david-nutt-82498025/
AtaiBeckley pipeline — https://www.ataibeckley.com/our-work/pipeline
BBC weight loss drugs comparison — https://www.bbc.com/news/articles/c981044pgvyo
David Nutt drug-harm chart — https://commons.wikimedia.org/wiki/File:HarmCausedByDrugsTable.svg
Matthew Walker, *Why We Sleep* — https://www.amazon.com/Why-We-Sleep-Unlocking-Dreams/dp/1501144316
Mayo Clinic report on resveratrol/red wine — https://www.mayoclinic.org/diseases-conditions/heart-disease/in-depth/red-wine/art-20048281
CNBC — atai's 2021 Wall Street debut — https://www.cnbc.com/2021/06/18/peter-thiel-backed-psychedelic-start-ups-shares-pop-in-wall-street-debut.html
Fortune article on Angermayer's uranium bet — https://fortune.com/crypto/2025/05/27/christian-angermayer-uranium-digital-german-billionaire-tether/
Robert Nelsen, ARCH Venture Partners — https://www.archventure.com/team/robert-nelsen/
📜 TRANSCRIPT
Read the full transcript here: https://flot.bio/episode/christian-angermayer-glp-1s/
💸 DONATE
We welcome donations from individuals and businesses to support our podcast and allow us to create even more content: https://www.paypal.me/PhilipHemme
⭐️ SPONSORSHIP
Ready to amplify your brand to influential leaders in biotech and biopharma? Contact nick@flot.bio and unlock sponsorship opportunities in our podcasts!
🫶 FOLLOW US
Newsletter: http://eepurl.com/h_fnmH
LinkedIn: https://www.linkedin.com/company/flot-bio/
X (Twitter): https://x.com/FlotBio
🙏 LIKE/FOLLOW/REVIEW
Did you enjoy the episode? Please hit the like and subscribe button. Also, please let me know your thoughts in the comments below.
🎙️ ABOUT FLOT.BIO
Flot.bio is a show to watch the best Europeans in biotech to help you grow. Hosted by Philip Hemme. 25k monthly views. Free.
⏰ TIMESTAMPS
[00:00:00] Intro
[00:02:38] Crazy Consumer Demand for Mounjaro, Zepbound and Ozempic
[00:07:45] Clinical Trials and Side-Effects: Can GLP-1s Benefit Non-Obese People?
[00:12:52] Prescriptions and Drug Risks
[00:25:57] The Trade-offs of Weight Loss, Testosterone
[00:33:18] Personal Optimization with Sleep and Diet
[00:40:44] Consumer Biotech: Vanity, Muscle and Sex
[00:47:12] AtaiBeckley and the Psychedelics Market
[00:56:25] Christian Angermayer: Uni Dropout to Multimillionaire
[01:03:53] Quick-Fire Questions

After ImCheck’s inception in 2015, Pierre took the helm through clinical development and guided the startup to a $1.2B buyout by Ipsen in 2025.
In a session at the Kadans Oncology Summit, he talks about how the exit materialised and the oncology space, including highlights from ASCO 2026, ADCs, in vivo CAR-T & checkpoint inhibitors.
He reveals some of the most shocking lessons he learned from his time at Imcheck.
---Learn more about Kadans’ Oncology Clusters, where oncology biotechs grow from start-up to global player: https://bit.ly/kadans-oncology---
⭐️ ABOUT THE SPEAKERPierre has 30 years of experience in the biopharmaceutical industry, including 9 years at ImCheck and more than 3 years as EVP, Chief Strategy Officer at Theravectys. Prior to this, he also spent 10 years in senior roles in Sanofi and Baxter Healthcare.
🔗 LINKS MENTIONED
Kadans Oncology Summit — https://www.kadansoncologysummit.com/
ImCheck Therapeutics — https://www.imchecktherapeutics.com/
ImCheck ASCO data (2025) — https://www.imchecktherapeutics.com/all-press-release/news/imcheck-reports-high-remission-rates-in-aml-patients-with-ict01-combination-therapy-at-asco-2025/
ImCheck acquisition by Ipsen (2025) — https://www.ipsen.com/press-release/ipsen-to-acquire-imcheck-therapeutics-expanding-its-leadership-in-oncology-strengthening-its-pipeline-3170788/
Pancreatic cancer ASCO data (2026) — https://www.asco.org/about-asco/press-center/multi-selective-ras-inhibitor-nearly-doubles-survival-pancreatic-cancer
Dominik Schumacher, Tubulis | Founder-led ADC Biotech | E19 — https://flot.bio/episode/dominik-schumacher-tubulis/
Ona Therapeutics raises $86.6M — https://ona-therapeutics.com/press-release/ona-therapeutics-raises-86m/
Moderna five-year cancer-vaccine data (2026) — https://www.merck.com/news/moderna-merck-announce-5-year-data-for-intismeran-autogene-in-combination-with-keytruda-pembrolizumab-demonstrated-sustained-improvement-in-the-primary-endpoint-of-recurrence-free-survival-i/
Sean Marett | BioNTech, Art of Dealmaking | E25 — https://flot.bio/episode/sean-marett-biontech-dealmaking/
Laurent Levy, Nanobiotix | Nanoparticles, Radiotherapy | E45— https://flot.bio/episode/laurent-levy-nanobiotix-nanoparticles-radiotherapy/
Marc de Garidel, Abivax | Ulcerative Colitis, Inflammation | E46 — https://flot.bio/episode/marc-de-garidel-abivax-ulcerative-colitis-inflammation/
Jeito Capital €1B fund — https://www.jeito.life/en/jeito-capital-record-eur-1-billion-fundraise-jeito-ii-fund-therapeutic-innovation/
ASCO 2026: ADC & In Vivo CAR-T Trends: ⁠https://flot.bio/pierre-d-epenoux-imcheck-adc-oncology/⁠

📜 TRANSCRIPT

Read the transcript here: https://flot.bio/episode/pierre-d-epenoux-imcheck-oncology/

💸 DONATE
We welcome donations from individuals and businesses to support our podcast and allow us to create even more content: https://www.paypal.me/PhilipHemme
⭐️ SPONSORSHIPReady to amplify your brand to influential leaders in biotech and biopharma? Contact nick@flot.bio and unlock sponsorship opportunities in our podcasts!
🫶 FOLLOW US
Newsletter: http://eepurl.com/h_fnmH
LinkedIn: https://www.linkedin.com/company/flot-bio/
X (Twitter): https://x.com/FlotBio
🙏 LIKE/FOLLOW/REVIEWDid you enjoy the episode? Please hit the like and subscribe button. Also, please let me know your thoughts in the comments below.
🎙️ ABOUT FLOT.BIO
Flot.bio is a show to watch the best Europeans in biotech to help you grow. Hosted by Philip Hemme. 25k monthly views. Free.
⏰ TIMESTAMPS
[00:00:00] Intro
[00:02:43] Highlights from ASCO 2026
[00:07:48] ADCs and In Vivo CAR-T: the Next Wave
[00:11:25] Pierre d’Epenoux Explains How to Stand Out in Oncology
[00:15:45] Checkpoint Inhibitors and the Rise of Combination Therapies
[00:21:23] ImCheck: from Inception to Ipsen Buyout
[00:28:36] Pipeline Focus and French pharma: Why ImCheck Chose Ipsen
[00:35:55] The Decision to Exit and Shocking Lessons
[00:42:05] Why Checkpoint Inhibitors Disappointed Beyond PD-1
[00:43:48] Quick-Fire Questions

Founded in 2010, the Institut Pasteur spinout PathoQuest sold to top CRO Charles River for $70M this year, a product of years of collaboration and stepwise investments.Jean‑François tells us how the exit unfolded, as well as the importance of biosafety and CMC as pharma and biotech outsource heavily and cell and gene therapies mature. We also cover how animal testing is disappearing from CMC and how France must nurture its biotech ecosystem.
---For transparency, this episode has been sponsored by PathoQuest.---
⭐️ ABOUT THE SPEAKER
Jean-François has more than 20 years of pharma leadership under his belt. Before his ten years at PathoQuest, he was a Senior Vice-President in charge of Ipsen’s GI-oncology and endocrinology franchise.He has an engineering degree and a master’s degree in Foreign Trade.
🔗 LINKS MENTIONED
CRL acquires PathoQuest (2026) — https://pathoquest.com/press-release-pathoquest-to-join-charles-river-laboratories-2/
Werner Lanthaler | Biopharma AI, CDMO, Antibody Optimization | E48 — https://flot.bio/episode/werner-lanthaler-biopharma-ai/
Charles River Laboratories and PathoQuest Expand Strategic Biologics Partnership (2018) — https://ir.criver.com/news-releases/news-release-details/charles-river-laboratories-and-pathoquest-expand-strategic
Charles River and PathoQuest validate viral safety assay (2023) — https://ir.criver.com/news-releases/news-release-details/charles-river-and-pathoquest-announce-publication-head-head
Philipp Baaske, NanoTemper | Bootstrapping in Biotech | E29 — https://flot.bio/episode/philipp-baaske-nanotemper-boostrapping-biotech/
Solexa acquisition by Illumina (2007) — https://investor.illumina.com/news/press-release-details/2006/Illumina-Signs-Definitive-Agreement-to-Acquire-Solexa/default.aspx
PathoQuest US lab opens in Wayne, PA (2022) — https://pathoquest.com/pathoquest-announce-the-opening-of-its-new-u-s-facility/
Thomas Ybert, DNA Script | DNA Printing & Synthesis | E27 — https://flot.bio/episode/thomas-ybert-dna-script-dna-printing/
Pascal Touchon | Cell Therapy, Jeito, Kymriah | E49 — https://flot.bio/episode/pascal-touchon-jeito/
First FDA-approved CAR-T — https://www.novartis.com/news/media-releases/novartis-receives-first-ever-fda-approval-car-t-cell-therapy-kymriahtm-ctl019-children-and-young-adults-b-cell-all-refractory-or-has-relapsed-least-twice
Marc de Garidel, Abivax | Ulcerative Colitis, Inflammation | E46— https://flot.bio/episode/marc-de-garidel-abivax-ulcerative-colitis-inflammation/
📜 TRANSCRIPT
Read the full transcript here: https://flot.bio/episode/jean-francois-brepson-pathoquest-cmc/

📖 BLOGS:
How Next-Generation Sequencing is Changing Biopharma Manufacturing: https://flot.bio/next-generation-sequencing-pathoquest/

💸 DONATE
We welcome donations from individuals and businesses to support our podcast and allow us to create even more content: https://www.paypal.me/PhilipHemme
⭐️ SPONSORSHIP
Ready to amplify your brand to influential leaders in biotech and biopharma? Contact nick@flot.bio and unlock sponsorship opportunities in our podcasts!
🫶 FOLLOW US
Newsletter: http://eepurl.com/h_fnmH
LinkedIn: https://www.linkedin.com/company/flot-bio/
X (Twitter): https://x.com/FlotBio
🙏 LIKE/FOLLOW/REVIEW
Did you enjoy the episode? Please hit the like and subscribe button. Also, please let me know your thoughts in the comments below.
🎙️ABOUT FLOT.BIO
Flot.bio is a show to watch the best Europeans in biotech to help you grow. Hosted by Philip Hemme. 25k monthly views. Free.
⏰ TIMESTAMPS
[00:00:00] Intro
[00:02:06] Big Pharma Is Heavily Outsourcing
[00:07:05] The $70M Charles River Acquisition
[00:11:18] CROs, PE and WuXI
[00:18:35] Biosafety with the "Intel Inside" Model 
[00:23:50] Replacing CMC Animal Testing: How the FDA Is Boosting Business 
[00:32:00] Lessons from US Expansion
[00:38:02] Biologics, Cell Therapy, and $15B of In Vivo CAR-T Bets 
[00:42:59] Jean-François Brepson: From Siberia to Startup CEO
[00:56:14] Quick-Fire: Animal Testing, AI, China, Elon Musk

When Hervé joined Incyte in 2014, the launch of lead product Jakafi in the US was choppy. By the time he left in 2025, he had grown their revenue from $300 million to a whopping $5 billion. We talk about the bureaucracy of Big Pharma, rare diseases, and why a biotech M&A supercycle isn’t as likely as you'd think.
---Discover the best biotech companies in 🇪🇺 with the FlotBio Map. https://bit.ly/4nXmKjN---
⭐️ ABOUT THE SPEAKER
Prior to his time at Incyte, Hervé led the oncology business unit at Novartis and had leading roles at Aventis (now Sanofi). He is currently on the boards of companies including Incyte, Pierre Fabre, & Bicycle Therapeutics.
🔗 LINKS MENTIONED
Pascal Touchon | Cell Therapy, Jeito, Kymriah | E49 —https://flot.bio/episode/pascal-touchon-jeito/
Alessandro Riva, Transgene | Cancer Vaccines, Oncolytic Viruses | E50— https://flot.bio/personalized-cancer-vaccine-oncolytic-viruses/
Penn and Novartis CAR-T alliance (2012) — https://penntoday.upenn.edu/news/university-pennsylvania-and-novartis-form-alliance-expand-use-personalized-t-cell-therapy-cance
Incyte and Novartis deal (2009) —https://investor.incyte.com/news-releases/news-release-details/incyte-announces-major-collaboration-and-license-agreement-two
Hoppenot steps down as Incyte CEO (2025) — https://investor.incyte.com/news-releases/news-release-details/incyte-announces-change-its-board-directors
argenx leadership transition (2026) —https://argenx.com/news/2026/press-release-3212418
BioNTech co-founders leadership transition (2026) — https://investors.biontech.de/news-releases/news-release-details/biontech-and-co-founders-announce-plan-pursue-next-generation
Incyte tumbles after combo therapy with Merck fails study (2018) — https://www.reuters.com/article/incyte-study/update-2-incyte-tumbles-after-combo-therapy-with-merck-fails-study-idUSL4N1RJ2HW/
Bristol-Myers Squibb receives accelerated approval of Opdivo (2014) — https://news.bms.com/news/details/2014/Bristol-Myers-Squibb-Receives-Accelerated-Approval-of-Opdivo-nivolumab-from-the-US-Food-and-Drug-Administration/default.aspx
U.S. FDA approves Padcev (2025) https://www.pfizer.com/news/press-release/press-release-detail/us-fda-approves-padcevr-plus-keytrudar-certain-patients
Fabrice Chouraqui, Pharming | Transgenic Rabbits, Rare Diseases | E43 — https://flot.bio/episode/fabrice-chouraqui-pharming-transgenic-rabbit/
Isomorphic Labs secures $2.1 billion funding (2026) — https://storage.googleapis.com/isomorphiclabs-website-public-artifacts/ISOMORPHIC_LABS_FUNDING_12-05-26.pdf
📜 TRANSCRIPT
Read the transcript here: https://flot.bio/episode/herve-hoppenot-incyte-jafaki/

📖 BLOGS:
The $6 Billion Excel Illusion: Why Biotech Pipeline Forecasting is Broken: https://flot.bio/biotech-pipeline-forecasting-herve-hoppenot/

💸 DONATE
We welcome donations from individuals and businesses to support our podcast and allow us to create even more content: https://www.paypal.me/PhilipHemme
⭐️ SPONSORSHIPReady to amplify your brand to influential leaders in biotech and biopharma? Contact nick@flot.bio and unlock sponsorship opportunities in our podcasts!
🫶 FOLLOW US
Newsletter: http://eepurl.com/h_fnmH
LinkedIn: https://www.linkedin.com/company/flot-bio/
X (Twitter): https://x.com/FlotBio
🙏 LIKE/FOLLOW/REVIEW
Did you enjoy the episode? Please hit the like and subscribe button. Also, please let me know your thoughts in the comments below.
🎙️ ABOUT FLOT.BIO
Flot.bio is a show to watch the best Europeans in biotech to help you grow. Hosted by Philip Hemme. 25k monthly views. Free.
⏰ TIMESTAMPS
[00:00:00] Intro
[00:02:59] Incyte legacy
[00:12:12] Leadership transitions in Incyte, argenx and BioNTech
[00:13:43] The JAK inhibitor market
[00:19:36] Why forecasting in pharma is broken
[00:29:17] Investor expectations & the Jakafi cliff 
[00:36:51] Biotechs trading under cash
[00:40:01] Hervé Hoppenot’s EU roots
[00:44:40] Big Pharma & bureaucracy
[00:51:58] Quick-fire questions

We admire the mountains of Austria with the co-founder of Curie.Bio, a founder-friendly fund that now manages $1.25B and backs 38 portfolio companies.We discuss Curie.Bio’s track record, with its most advanced portfolio candidate Forward Therapeutics in Phase I.We also talk about major bottom-up successes including argenx, Ascendis and Genmab, and how life sciences investing differs from tech investing.Christoph also explains his ‘rebel’ mindset and why founders shouldn’t accept the status quo.
---This episode is brought to you by Avance, where European biotech turns for trusted financial advice. Learn more at https://bit.ly/flot-avance---
⭐️ ABOUT THE SPEAKER
Christoph co-founded of Curie.Bio in 2022, after serving as Partner at Third Rock Ventures for 6 years. He also had leading roles at Blueprint Medicines for ten years, and at MOMA Therapeutics for one year.He has also been an Adjunct Associate Professor at Johns Hopkins University for more than 20 years, with past roles at Celsius Therapeutics, Sanofi, and Novartis. 🔗 LINKS MENTIONED
Curie.Bio — https://curie.bio/
Christoph Lengauer — https://www.linkedin.com/in/christoph-lengauer-75b7961b/
Sanofi to acquire Blueprint Medicines — https://www.sanofi.com/en/media-room/press-releases/2025/2025-06-02-05-00-00-3091541
Forward Therapeutics Announces $50 Million Series A Financing —https://forward-tx.com/press-release/forward-therapeutics-announces-50-million-series-a-financing/
Gilead to Acquire Tubulis — https://www.gilead.com/news/news-details/2026/gilead-to-acquire-tubulis-adding-potentially-best-in-class-antibody-drug-conjugate-and-next-generation-platform-to-further-strengthen-oncology-pipeline
Dominik Schumacher, Tubulis 🇩🇪 | Founder-led ADC Biotech ⭐️ | E19 — https://flot.bio/episode/dominik-schumacher-tubulis/
Sander Slootweg, Forbion 🇳🇱 | European Biotech Investment, Venture Capital | E56 — https://flot.bio/episode/sander-slootweg-forbion-eu-biotech-investment/
📜 TRANSCRIPT
Read the full transcript here: https://flot.bio/episode/christoph-lengauer-curiebio-biotech-founders/

📖 BLOGS BASED ON THIS EPISODE:
The Biotech Equity Gap: Why Curie.Bio is Re-Writing the Founder Playbook: https://flot.bio/biotech-equity-founder/

💸 DONATE
We welcome donations from individuals and businesses to support our podcast and allow us to create even more content: https://www.paypal.me/PhilipHemme
⭐️ SPONSORSHIP
Ready to amplify your brand to influential leaders in biotech and biopharma? Contact nick@flot.bio and unlock sponsorship opportunities in our podcasts!
🫶 FOLLOW US
Newsletter: http://eepurl.com/h_fnmH
LinkedIn: https://www.linkedin.com/company/flot-bio/
X (Twitter): https://x.com/FlotBio
🙏 LIKE/FOLLOW/REVIEW
Did you enjoy the episode? Please hit the like and subscribe button. Also, please let me know your thoughts in the comments below.
🎙️ ABOUT FLOT.BIO
Flot.bio is a show to watch the best Europeans in biotech to help you grow. Hosted by Philip Hemme. 25k monthly views. Free.⏰ TIMESTAMPS
[00:00:00] Intro
[00:03:05] Curie.Bio: 38 portfolio companies in just three years
[00:09:29] The four buckets of biotech venture capital
[00:15:42] Why life sciences investing is harder than tech investing
[00:28:28] Searching for European biotech innovation
[00:38:00] Founder-friendly equity shares
[00:55:15] argenx, Genmab and Ascendis: Bottom-up biotech successes
[01:03:37] Blueprint Medicines: From struggle to a $9B sale
[01:09:03] Christoph Lengauer the disruptor
[01:13:37] Quick-fire questions